12/4/2014
`
`FiercePharma
`
`With nod, Roche's Kadcyla should quickly become blockbuster FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`Topics: Regulatory
`With nod, Roche's Kadcyla should quickly
`become blockbuster
`FDA approves highly anticipated treatment for latestage breast cancer
`February 22, 2013 | By Eric Palmer
`
`At an earnings call last month, Roche ($RHHBY) CEO Severin Schwan crowed a
`bit about the Swiss company's future, pointing to drugs in the pipeline like its highly
`anticipated breast cancer treatment and potential blockbuster TDM1. Today, the
`FDA gave approval to the drug, which will be marketed as Kadcyla, for patients
`with HER2positive, latestage (metastatic) breast cancer. The drug will have an
`estimated monthly cost of $9,800, or about $94,000 for a full course of treatments,
`Forbes reports. As FierceBiotech points out, forecasts have put peak sales of the
`breakthrough antibody drug conjugate at between $2 billion and $5 billion. Roche
`has reported that in a Phase III study, the drug reduced the risk of death among
`patients by 32% compared to the standardofcare arm. Story | More
`
`The Biotech Primer: An insider's guide to the science driving the biotech
`and pharma industries
`
`This 200page book takes an indepth look at the biotech industry and the science that drives
`it. Although the industry itself is constantly changing, these fundamental concepts upon which
`it is built will remain important for years to come and decisionmakers who understand these
`fundamentals will be better able to evaluate and predict new trends. Click here to buy today!
`
`Sign up for our free newsletter
`
`EMAIL ADDRESS
`
`SHARE
`
`11
`
`Tweet
`
`12
`
`Share
`
`0
`
`Like
`
`0
`
`TOOLS
`
`Comment
`
`Print
`
`Contact
`Author
`
`FOLLOW US
`
`J O I N 1 5 0 ,0 0 0 + I NS I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`EMAIL ADDRESS
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company
`news and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`Sanofi, Viehbacher accused of kickback scheme in
`whistleblower suit
`Actavis cuts 200 U.S jobs, perhaps providing a
`glimpse of what is in store at Allergan
`BMS makes cuts in China, reports say up to 1,000
`Pfizer believes a dose of confidence will help it sell
`biosimilars
`AstraZeneca paytodelay could cost it and the
`industry billions of dollars
`
`THE LIBRARY: EBOOK
`eBook | Secure File Sharing in a Disaggregated
`Industry
`
`| SPONSORED BY: INTRALINKS | PUBLISHER: OCTOBER
`
`http://www.fiercepharma.com/story/nodrocheskadcylashouldquicklybecomeblockbuster/20130222
`
`1/3
`
`IMMUNOGEN 2253, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`FiercePharma
`
`With nod, Roche's Kadcyla should quickly become blockbuster FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`Topics: Regulatory
`With nod, Roche's Kadcyla should quickly
`become blockbuster
`FDA approves highly anticipated treatment for latestage breast cancer
`February 22, 2013 | By Eric Palmer
`
`At an earnings call last month, Roche ($RHHBY) CEO Severin Schwan crowed a
`bit about the Swiss company's future, pointing to drugs in the pipeline like its highly
`anticipated breast cancer treatment and potential blockbuster TDM1. Today, the
`FDA gave approval to the drug, which will be marketed as Kadcyla, for patients
`with HER2positive, latestage (metastatic) breast cancer. The drug will have an
`estimated monthly cost of $9,800, or about $94,000 for a full course of treatments,
`Forbes reports. As FierceBiotech points out, forecasts have put peak sales of the
`breakthrough antibody drug conjugate at between $2 billion and $5 billion. Roche
`has reported that in a Phase III study, the drug reduced the risk of death among
`patients by 32% compared to the standardofcare arm. Story | More
`
`The Biotech Primer: An insider's guide to the science driving the biotech
`and pharma industries
`
`This 200page book takes an indepth look at the biotech industry and the science that drives
`it. Although the industry itself is constantly changing, these fundamental concepts upon which
`it is built will remain important for years to come and decisionmakers who understand these
`fundamentals will be better able to evaluate and predict new trends. Click here to buy today!
`
`Sign up for our free newsletter
`
`EMAIL ADDRESS
`
`SHARE
`
`11
`
`Tweet
`
`12
`
`Share
`
`0
`
`Like
`
`0
`
`TOOLS
`
`Comment
`
`
`Contact
`Author
`
`FOLLOW US
`
`J O I N 1 5 0 ,0 0 0 + I NS I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`EMAIL ADDRESS
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company
`news and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`Sanofi, Viehbacher accused of kickback scheme in
`whistleblower suit
`Actavis cuts 200 U.S jobs, perhaps providing a
`glimpse of what is in store at Allergan
`BMS makes cuts in China, reports say up to 1,000
`Pfizer believes a dose of confidence will help it sell
`biosimilars
`AstraZeneca paytodelay could cost it and the
`industry billions of dollars
`
`THE LIBRARY: EBOOK
`eBook | Secure File Sharing in a Disaggregated
`Industry
`
`| SPONSORED BY: INTRALINKS | PUBLISHER: OCTOBER
`
`http://www.fiercepharma.com/story/nodrocheskadcylashouldquicklybecomeblockbuster/20130222
`
`1/3
`
`IMMUNOGEN 2253, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`12/4/2014
`
`Reprint
`
`Filed Under Breast Cancer, Roche, TDM1
`
`COMMENTS
`
`0 Comments
`
`FiercePharma
`
`Sort by Best
`
`Start the discussion…
`
`With nod, Roche's Kadcyla should quickly become blockbuster FiercePharma
`31
`
`The shift from fullyintegrated
`pharmaceutical companies to the
`more externalized, networked model of R&D is
`increasingly prominent. This eBook looks into
`the need for secure, cloudbased platforms to
`share files and collaborate. Download today!
`
` Login
`
`
`
`MORE ITEMS
`
`Share ⤤
`
`Favorite ★
`
`ALSO ON FIERCEPHARMA
`Report: Orphan drugs to nab 19% of
`drug sales by 2020if payers don't …
`2 comments • a month ago
`saw123 — I liked the segue from orphan
`drugs to Gilead's drugs for a large
`market. The orphan drugs are …
`
`WHAT'S THIS?
`GSK ready to ax hundreds in U.S.,
`sources tell Bloomberg
`1 comment • 3 days ago
`aharrell2000 — Typically what happens
`when forecasts are not
`met.....http://ah2andbeyond.com/social...
`
`U.K. gatekeepers toughest on cancer
`medsand getting tougher all the time
`1 comment • 10 days ago
`OllieProphet — The Death Panels,
`described so clearly during the ACA
`(ObamaCare) debates by its …
`
`Lundbeck CEO exits in disgrace,
`endangering key new launches
`3 comments • 10 days ago
`M — I'm clearly stupid.
`
`Subscribe
`
`✉
`
`d
`
`Add Disqus to your site
`
`Privacy
`
`
`
`LATEST COMMENTARY
`
`Pfizer believes a dose of confidence will help it sell
`biosimilars
`We publish, you pick: FiercePharma's 10 bestread
`stories of 2014
`Who are the stars of personalized meds? Roche,
`Novartis and J&J
`Takeda scrambles to fix glitches in Contrave direct
`delivery launch
`Sanofi's U.S. sales team gets its closeupand a
`promised makeover
`
`EVENTS
`
`DrugDev Presents: SCRS Webinar Sites
`Report How to Make Life Easy for Them
`
`7th annual PreFilled Syringes
`2829 January 2015 — London, UK
`
`FierceBiotech presents: Executive
`Breakfast at the J.P. Morgan Healthcare
`Conference
`January 13, 2015 — San Francisco, CA
`MORE EVENTS
`
`
`
`PRESS RELEASES
`PneumRx Acquired by BTG plc for up to $475 Million
`KindredBio Announces Update on AtoKin and Atopic Dermatitis
`Program
`Forbion Announces Sale of Portfolio Company PneumRx to BTG for up
`
`FEATURED JOBS
`> Need a job? Need to hire? Visit our jobs site.
`
`http://www.fiercepharma.com/story/nodrocheskadcylashouldquicklybecomeblockbuster/20130222
`
`2/3
`
`Be the first to comment.
`
`IMMUNOGEN 2253, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`With nod, Roche's Kadcyla should quickly become blockbuster FiercePharma
`
`12/4/2014
`to EUR 385M (USD 475M)
`Powdered measles vaccine found safe in early clinical trials
`Novavax (NVAX) Receives FDA FastTrack Designation for RSV F
`Vaccine Candidate
`More Press Releases
`
`A publication of
`
`FiercePharma is the pharma
`industry's daily monitor, with
`a special focus on
`pharmaceutical company
`news and the market
`development of FDA
`approved products. Join
`150,000+ pharma industry
`leaders who get
`FiercePharma via daily
`email. Click here to get your
`free weekly email briefing
`today!
`
`The FierceMarkets Network:
`Telecom
`FierceCable
`FierceDeveloper
`FierceWireless:Europe
`FierceWirelessTech
`FierceOnlineVideo
`FierceTelecom
`FierceWireless
`
`Marketing & Retail
`FierceCMO
`FierceMobileMarketer
`FierceRetail
`FierceRetailIT
`FierceMobileRetail
`
`Healthcare
`FierceEMR
`FierceHealthcare
`FierceHealthFinance
`FierceHealthIT
`FierceHealthPayer
`FierceHealthPayerAntiFraud
`FierceMedicalImaging
`FierceMobileHealthcare
`FiercePracticeManagement
`Hospital Impact
`
`Government
`FierceGovernment
`FierceGovernmentIT
`FierceHomelandSecurity
`FierceMobileGovernment
`
`Life Sciences
`FierceBiotechResearch
`FierceBiotech
`FierceBiotechIT
`FierceCRO
`FierceDiagnostics
`FierceDrugDelivery
`FierceMedicalDevices
`FiercePharma
`FiercePharmaManufacturing
`FiercePharmaMarketing
`FierceVaccines
`FierceAnimalHealth
`
`Enterprise IT
`FierceBigData
`FierceCIO
`FierceContentManagement
`FierceEnterprise
`Communications
`FierceITSecurity
`FierceMobileIT
`
`Energy
`FierceEnergy
`FierceSmartGrid
`
`Finance
`FierceCFO
`FierceFinanceIT
`
`Home Subscribe Manage Newsletter Subscriptions Advertise Contact Mobile Apps RSS Privacy Editors List in Marketplace
`© 2014 FierceMarkets, a division of Questex Media Group LLC. All rights reserved.
`
`http://www.fiercepharma.com/story/nodrocheskadcylashouldquicklybecomeblockbuster/20130222
`
`3/3
`
`IMMUNOGEN 2253, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
